Beam Therapeutics Inc (BEAM)

Mar 12, 2026

Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView

Mar 12, 2026

Mar 06, 2026

Liquidity Mapping Around (BEAM) Price Events - Stock Traders Daily

Mar 06, 2026

Mar 05, 2026

According to a document submitted to the U.S. Securities and Exchange Commission (SEC) on March 2, Beam Therapeutics Inc. and Bio Palette have jointly decided to terminate the licensing agreement signed by both parties on March 27, 2019. - Bitget

Mar 05, 2026

Mar 05, 2026

Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit - TipRanks

Mar 05, 2026

Mar 05, 2026

Beam Therapeutics Inc. Terminates License Agreement with Bio Palette Co., Ltd - marketscreener.com

Mar 05, 2026

Mar 05, 2026

HC Wainwright Predicts Weaker Earnings for Beam Therapeutics - MarketBeat

Mar 05, 2026

Mar 05, 2026

JPMorgan Chase & Co. Trims Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 05, 2026

Mar 05, 2026

ARK Investment Boosts Stake in Beam Therapeutics - National Today

Mar 05, 2026

Mar 05, 2026

Amova Asset Management Americas Inc. Buys 103,939 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 05, 2026

Mar 05, 2026

ARK Investment Management LLC Increases Position in Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 05, 2026

Mar 04, 2026

Beam Therapeutics Earnings Call Highlights PKU Pivot - TipRanks

Mar 04, 2026

Mar 04, 2026

What is HC Wainwright's Forecast for BEAM Q1 Earnings? - MarketBeat

Mar 04, 2026

Mar 03, 2026

Mintz Advises Sixth Street On $500 Million Strategic Financing Facility With Beam Therapeutics - Mondaq

Mar 03, 2026

Mar 03, 2026

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - mx.advfn.com

Mar 03, 2026

Mar 03, 2026

H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Australia

Mar 03, 2026

Mar 03, 2026

H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com Nigeria

Mar 03, 2026

Mar 03, 2026

Contrarius Group Holdings Ltd Buys Shares of 1,533,269 Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 03, 2026

Mar 02, 2026

BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 02, 2026

Mar 02, 2026

Vanguard Group Inc. Sells 455,440 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat

Mar 02, 2026

Feb 28, 2026

BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 28, 2026

Feb 28, 2026

Beam Therapeutics (NASDAQ:BEAM) Raised to Hold at Wall Street Zen - MarketBeat

Feb 28, 2026

Feb 28, 2026

BEAM.O PE Ratio & Valuation, Is BEAM.O Overvalued - Intellectia AI

Feb 28, 2026

Feb 28, 2026

RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here’s Why - Yahoo Finance

Feb 28, 2026

Feb 28, 2026

BEAM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Should You Buy Beam Therapeutics Inc (BEAM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI

Feb 27, 2026

Feb 27, 2026

Assessing Beam Therapeutics (BEAM) Valuation After Q4 Earnings Surprise Credit Facility And PKU Program Launch - simplywall.st

Feb 27, 2026

Feb 27, 2026

RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why - Bitget

Feb 27, 2026

Feb 27, 2026

Beam Therapeutics: Great Potential, But Patience Is Needed (NASDAQ:BEAM) - Seeking Alpha

Feb 27, 2026

Feb 27, 2026

Beam Therapeutics reveals new program for PKU - BioWorld MedTech

Feb 27, 2026

Feb 26, 2026

Bernstein SocGen cuts Beam Therapeutics stock price target on valuation By Investing.com - Investing.com Canada

Feb 26, 2026

Feb 26, 2026

Bernstein SocGen cuts Beam Therapeutics stock price target on valuation - Investing.com

Feb 26, 2026

Feb 26, 2026

Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing - Yahoo Finance

Feb 26, 2026

Feb 25, 2026

Beam Therapeutics (BEAM) Quarterly Profit Surprises Loss Narrative With US$244.3 Million Net Income - simplywall.st

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.3%Time to Sell? - MarketBeat

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - WilmerHale

Feb 25, 2026

Feb 25, 2026

BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00 - MarketBeat

Feb 25, 2026

Feb 25, 2026

BEAM Shares See Target Price Boost by RBC Capital | BEAM Stock N - GuruFocus

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics Stock Surges 14% on Strategic Financing: How the $500M Agreement Secures a $156 Target - TIKR.com

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics Opens with 7.83% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics Hits Day High with 17.04% Surge in Stock Price - Markets Mojo

Feb 25, 2026

Feb 25, 2026

Wedbush Raises BEAM Price Target to $65, Maintains Outperform Ra - GuruFocus

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics (NASDAQ:BEAM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics (BEAM) stock edges up premarket after 14% jump on results, $500 million facility - Bez Kabli

Feb 25, 2026

Feb 25, 2026

RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector PerformSpeculative Risk Rating - marketscreener.com

Feb 25, 2026

Feb 25, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 25, 2026

Feb 25, 2026

Mintz Advises Sixth Street on $500 Million Strategic Financing Facility with Beam Therapeutics - Mintz

Feb 25, 2026

Feb 25, 2026

Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus

Feb 25, 2026

Feb 24, 2026

Beam Therapeutics Inc. (BEAM) Stock Analysis: Exploring a 72.96% Potential Upside in the Biotech Innovator - DirectorsTalk Interviews

Feb 24, 2026

Feb 24, 2026

Beam Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 24, 2026

Feb 24, 2026

Earnings Call Summary | Beam Therapeutics(BEAM.US) Q4 2025 Earnings Conference - 富途牛牛

Feb 24, 2026

Feb 24, 2026

[144] Beam Therapeutics Inc. SEC Filing - Stock Titan

Feb 24, 2026

Feb 24, 2026

BofA raises Beam Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Australia

Feb 24, 2026

Feb 24, 2026

Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: Strategic Financing and ... By GuruFocus - Investing.com Canada

Feb 24, 2026

Feb 24, 2026

Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: S - GuruFocus

Feb 24, 2026

Feb 24, 2026

What's Going On With Beam Therapeutics Stock?Beam Therapeutics (NASDAQ:BEAM) - Benzinga

Feb 24, 2026

Feb 24, 2026

BofA raises Beam Therapeutics stock price target on pipeline progress - Investing.com

Feb 24, 2026

Feb 24, 2026

Beam Therapeutics Shares Rise After Swinging to Q4 Adjusted Earnings - marketscreener.com

Feb 24, 2026

Feb 24, 2026

Analyst bullish on Beam Therapeutics (BEAM) over drug program trajectory - MSN

Feb 24, 2026

Feb 24, 2026

Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

Feb 24, 2026

Feb 24, 2026

Beam Therapeutics Inc. announced that it expects to receive $500 million in funding - marketscreener.com

Feb 24, 2026

Feb 24, 2026

Wedbush Raises Beam Therapeutics Price Target to $65 From $57, Maintains Outperform Rating - marketscreener.com

Feb 24, 2026

Feb 24, 2026

Beam Therapeutics Q4 Earnings Call Highlights - MarketBeat

Feb 24, 2026